Italy, Update, Reform, Agenda, Pharma Pricing

Italy: update on the reform agenda

At World Pharma Pricing & Market Access Congress 2014, Dr Giovanni Tafuri, AIFA, gave a presentation on  “Italy: update on the reform agenda” Tafuri’s presentation discusses his thoughts on how to solve current problems like how to balance fast market access with available resources, how to harmonize market access across regions, and  how to cope with uncertainty when deciding on pricing …

Spotlight back on Antibiotics Market

Thought to be undervalued and overshadowed by the bigger revenue draw from blockbuster drug manufacturing, Merck’s ($MRK) recent acquisition of Cubist ($CBST) might have placed a spotlight back to the Antibiotics Market. Unlike its compatriots in the biologic therapeutics market, antibiotics target specifically on bacterial infections. More often than not, the efficacy of antibiotics decreases through the misuse of antibiotics. …

Value, drugs, payers

How Do You Demonstrate Value For Innovative Drugs To Payers?

  At Evidence EU 2014,  Prof. Dr. Markus Kosch, Pfizer Oncology, Portfolio Lead Europe, Africa/Middle East, Pfizer, gave a presentation on “How Do You Demonstrate Value For Innovative Drugs To Payers?” Download and learn: Value of innovation to public health PFS vs. OS the “wrong comparator” –can STC help? Real world data Download presentation Found this interesting? Join us at …

insights, ebook, evidence, real world evidence, rwe, evidence europe 2015

Ebook: Essential insights into real world evidence

Successful companies need to incorporate real world evidence in clinical trials, post approval studies and in payer engagement programmes. Needless to say, this shift is causing monumental changes in how the industry operates, how the payers engage with them and how service providers support pharma. This raises some important questions. What is value? What parts of our existing business model do we keep and what …

pharma, pharma pricing, market access, drug, considerations, pharma pricing and market access europe

Ebook: Key Considerations for Market Access

In an era of austerity and rising health care costs, payers are exerting greater influence over pharmaceutical markets and demanding insight into a drug’s value and cost effectiveness. Creating an effective market access strategy is vital for a successful product launch. You need to integrate the payer perspective throughout the development and decisions making process. In this ebook, we share …

Netherlands, Anticipate, Future, Pharma, Pharma Pricing

The Netherlands: How to anticipate future pharma and healthcare dynamics?

At the World Pharma Pricing and Market Access Congress 2014, Cornelis Boersma, Head Market Access GSK, gave a presentation “The Netherlands: How to anticipate future pharma and healthcare dynamics?” Boersma’s presentation reflects his attitude “Change towards a predictable and sustainable decision-making system!” Download and learn: Trends in healthcare and pharma expenditures Dutch Pharma system under development NL policy: Implementation of ‘Vuvuzela’ Market Access and …

value, assessment

From promise to reality: how is real world evidence shaping the future of healthcare?

At Evidence EU  2014, David Haslam, Chairman NICE gave a presentation on “From promise to reality: how is real world evidence shaping the future of healthcare?” This presentation explores NICE’s role in improving outcomes for people as well as focusing on challenges (uptake, implementation and pushy patients) and value-based assessment. Download and learn: The multi morbidity challenge Value Based Assessment …

Results, Benefit Assessment, Price, negotiation, Pharma Pricing

Latest results of early benefit assessments and price negotiations

At Pharma Pricing 2014, Meriem Bouslouk PhD, Pharmaceuticals Department, Federal Joint Committee Germany gave a presentation “Latest results of early benefit assessments and price negotiations” Download and learn: Assessment principles- Key points Consultations with the G-BA Orphan Drugs Price negotiations / Arbitration Decisions / OPT-OUTS G-BA vision at European level Licensing and reimbursing: harmonization? Download presentation Found this interesting? You might …

Understanding the path needed to bring your cell therapy to market

Robert A. Preti, PhD, President, PCT; Chief Science Officer, NBS joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress ‘Understanding the path needed to bring your cell therapy to market.’ Download this presentation now to find out: What problem are we trying to solve? Development by Design (DbD) Quality by Design (QbD) Assembling a commercial manufacturing …

Value, European, Healthcare, Market

How to develop a compelling value proposition in the current European healthcare market

At Evidence EU 2014, Caroline Gadd, Otsuka Pharmaceuticals, gave a presentation on “How to develop a compelling value proposition in the current European healthcare market”. Gadd’s presentation highlights the importance of value proposition, demonstrating that a successful proposition is moving towards a customer centric approach as well as being able to support the whole market. Download and Learn: The value proposition as …